Mucins and CD56 as markers of tumour invasion and prognosis in periampullary cancer

British Journal of Surgery

Volumn 97, Issue 8, 2010, Pages 1269-1278

  Aloysius, M M ^a   Zaitoun, A M ^b   Awad, S ^a   Ilyas, M ^b   Rowlands, B J ^a   Lobo, D N ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; MUCIN; TUMOR MARKER;

AGED; ARTICLE; BILE DUCT TUMOR; CANCER INVASION; CHRONIC PANCREATITIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; VATER PAPILLA;

AGED; AMPULLA OF VATER; ANTIGENS, CD56; COMMON BILE DUCT NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUCINS; NEOPLASM INVASIVENESS; PANCREATITIS, CHRONIC; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955216380     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.7107     Document Type: Article

References (39)

1. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009; 9: 874-885.
2. Miasaki Y, Oka. M, Ogura Y, Ueno T, Nishihara K, Tangoku A et al. Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions, and pancreatic ductal, adenocarcinoma.. Hepatogastroenterology 1999; 46: 2240-2245.
3. Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 2005; 18: 1295-1304.
4. Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996; 7: 565-577.
5. Yonezawa S, Nakamura A, Horinouchi M, Sato E. The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms. J Hepatobiliary Pancreat Surg 2002; 9: 328-34.1.
6. Park HU, Kim JW, Kim GE, Bae HI, Crawley SC, Yang SC et al. Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia. Pancreas 2003; 26: e48-e54.
7. Andrianifahanana M, Moniaux N, Schmied BM, Ringel J, Friess H, Hollingsworth MA et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a. potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res 2001; 7: 4033-4040.
8. Chaturvedi. P, Singh AP, Moniaux N, Senapati. S, Chakraborty S, Meza JL et al. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol. Cancer Res 2007; 5: 309-320.
9. Singh AP, Moniaux N, Chauhan SC, Meza JL, Batra SK. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res 2004; 64: 622-630.
10. Vandenhaute B, Buisine MP, Debailleul V, Clement B, Moniaux N, Dieu MC et al. Mucin gene expression in biliary epithelial cells. J Hepatol 1997; 27: 1057-1066.
11. Shibahara H, Tamada S, Higashi M, Goto M, Batra SK, Hollingsworth MA et al. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-niass forming type. Hepatology 2004; 39: 220-229.
12. Saitou M, Goto M, Horinouchi M., Tamada. S, Nagata K, Hamada. T et al. MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma, of the pancreas. J Clin Pathol2005; 58: 845-852.
13. Matull WR, Andreola F, Loh A, Adiguzel Z, Deheragoda. M, Qureshi U et al. MUC4 and. MUC5AC are highly specific tumour-associated mucins in biliary tract cancer. BrJ Cancer 2008; 98: 1675-1681.
14. Jinfeng M, Kimura W, Hirai I, Sakurai F, Moriya T, Mizutani M. Expression of MUC5AC and MUC6 in invasive ductal carcinoma of the pancreas and relationship with prognosis. Int J Gastrointest Cancer 2003; 34: 9-18.
15. Seki H, Koyama K, Tanaka J, Sato Y, Umezawa A. Neural cell adhesion molecule and perineural invasion in gallbladder cancer. J Surg Oncol 1995; 58: 97-100.
16. Seki H, Tanaka J, Sato Y, Kato Y, Umezawa A, Koyama. K. Neural cell adhesion molecule (NCAM) and perineural invasion in bile duct cancer. J Surg Oncol 1993; 53: 78-83.
17. Aloysius MM, Zaitoun AM, Bates TE, Albasri A, Ilyas M, Rowlands BJ et al. Complete absence of M2-pyruvate kinase expression in benign pancreatic ductal epithelium and pancreaticobiliary and duodenal neoplasia. BMC Cancer 2009; 9: 327.
18. Aloysius MM, Zaitoun AM, Bates TE, Ilyas M, Constantin-Teodosiu D, Rowlands BJ et al. Immunohistochemical expression of mitochondrial membrane complexes (MMCs) I, III, IV and V in malignant and benign periampullary epithelium: a potential target for drug therapy of periampullary cancer? BMC Cancer 2010; 10: 80.
19. McCarty KS Jr, Miller LS, Cox EB, Konrath J, MeCarty KS Sr. Estrogen receptor analyses. Correlation of biochemical, and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109: 716-721.
20. Moniaux N, Andrianifahanana M, Brand RE, Batra. SK. Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. Br J Cancer 2004; 91: 1633-1638.
21. Westgaard A, Schjolberg AR, Cvancarova M, Eide TJ, Clausen OP, Gladhaug IP. Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours. Histopathology 2009; 54: 337-347.
22. Klöppel G, Adsay NV. Chronic pancreatitis and the differential diagnosis versus pancreatic cancer. Arch Pathol Lab Med 2009; 133: 382-387.
23. Monges GM, Mathoulin-Portier MP, Acres RB, Houvenaeghel GF, Giovannini MF, SeitzJF et al. Differential MUC 1 expression in normal and neoplastic human pancreatic tissue. An immunohistochemical study of 60 samples. Am J Clin Pathol 1999; 112: 635-640.
24. Nagata K, Horinouchi M, Saitou M, Higashi M, Nomoto M, Goto M et al. Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliary Pancrcat Surg 2007; 14: 243-254.
25. Terada T, Ohta T, Sasaki M, Nakanuma Y, Kim YS. Expression of MUC apomucins in normal pancreas and pancreatic tumours. J Pathol 1996; 180: 160-165.
26. Chhieng DC, Benson E, Eltoum I, Eloubeidi MA, Jhala N, Jhala D et al. MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration. Cancer 2003;99:365-371.
27. Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer 1993;72:3641-3647.
28. Levi E, Klimstra DS, Andea A, Basturk O, Adsay NV. MUC1 and MUC2 in pancreatic neoplasia. J Clin Pathol 2004; 57: 456-462.
29. Ahn DH, Crawley SC, Hokari R, Kato S, Yang SC, Li JD et al. TNF-alpha activates MUC2 transcription via. NF-kappaB but inhibits via JNK activation. Cell Physiol Biochem 2005; 15: 29-40.
30. Ho SB, Dvorak LA, Moor RE, Jacobson AC, Frey MR, Corredor J et al. Cysteine-rich domains of muc3 intestinal mucin promote cell migration, inhibit apoptosis, and accelerate wound healing. Gastroenterology 2006; 131: 1501-1517.
31. Komatsu M, Tatum L, Altman NH, Carothers Carraway CA, Carraway KL. Potentiation of metastasis by cell surface sialomucin complex (rat MUC4), a multifunctional anti-adhesive glycoprotein. IntJ Cancer 2000; 87: 480-486.
32. Burdick MD, Harris A, Reid CJ, Iwamura T, Hollingsworth MA. Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumor cell lines. J Biol Chem 1997; 272: 24 198-24 202.
33. Komatsu M, Yee L, Carraway KL. Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells. Cancer Res 1999; 59: 2229-2236.
34. Sonoue H, Suda K, Nobukawa B, Abe H. Cytokeratin (CK7, CK20) and MUC5AC expression in ampullary carcinoma. J Jpn Bil Assoc 2006; 20: 473-478.
35. Boonla C, Sripa B, Thuwajit P, Cha-On U, Puapairoj A, Miwa M et al. MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma. Work J Gastroenterol 2005; 11: 4939-4946.
36. Yonezawa S, Horinouchi M, Osako M, Kubo M, Takao S, Arimura Y et al. Gene expression of gastric type mucin (MUC5AC) in pancreatic tumors: its relationship with the biological behavior of the tumor. Pathol Int 1999; 49: 45-54.
37. Rong Y, Jin D, Wu W, Lou W, Wang D, Kuang T et al. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine, BMC Cancer 2009; 9: 191.
38. Fons G, Hasibuan SM, van der Velden J, ten Kate FJ. Validation of tissue microarray technology in endometrioid cancer of the endometrium. J Clin Pathol 2007; 60: 500-503.
39. Richani K, Romero R, Kim YM, Cushenberry E, Soto E, Han YM et al. Tissue microarray: an effective high-throughput method to study the placenta for clinical and research purposes. J Matern Fetal Neonatal Med 2006; 19: 509-515.